恩格列净治疗射血分数降低心力衰竭患者的效果  

The Effect of Empaqliflozin in the Treatment of Ejection Fraction Reduction in Patients with Heart Failure

作　　者：王贵亮[1] WANG Guiliang(Department of Cadiology three spa area,Jilin City Central Hospital of Jilin,Jilin 132000)

机构地区：[1]吉林市中心医院心内科,吉林吉林132000

出　　处：《智慧健康》2024年第31期45-48,共4页Smart Healthcare

摘　　要：目的 观察钠—葡萄糖协同转运蛋白2(SGLT2)抑制剂恩格列净治疗射血分数降低慢性心力衰竭(HF-rEF)的效果。方法 将2019年6月—2022年1月吉林市市中心医院心血管内科收治的94例HF-rEF患者按照随机数字表法分为对照组(47例)和观察组(47例)。其中,对照组采用常规抗心力衰竭治疗,观察组在常规治疗基础上加恩格列净,比较治疗前、后两组患者6min步行距离(6MWD)、氨基末端脑钠肽前体(NT-proBNP)、肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP)、hs-cTnT、左心室射血分数(LVEF)、左室舒张末期内径(LVIDd)、左室收缩末期内径(LVIDs)水平、心输出量(CO)、E/A值、再住院率以及不良反应。结果 观察组6MWD、NT-proBNP、TNF-α、hs-CRP、hs-cTnT、LVEF、LVIDd、心输出量(CO)、E/A值、临床疗效、再住院率改善情况明显优于对照组(P<0.05)。两组的LVIDs、不良反应发生率对比,差异无统计学意义(P>0.05)。结论 在HF-rEF患者中,恩格列净治疗射血分数降低型心力衰竭疗效确切,可以显著地改善患者临床症状、心脏功能以及生活质量,不良反应少,安全性高。Aim:to observe the efficacy of sodium-glucose co-transporter 2(SGLT2)inhibitor empagliflozin in the treatment of chronic heart failure(HF-rEF)with reduced ejection fraction.Methods:from June 2019 to January 2022,94 patients with HF-rEF were randomly divided into Control Group(n=47)and Observation Group(n=47).The control group was treated with routine anti-heart failure therapy,and the observation group was treated with Empagliflozin on the basis of routine therapy,sixminute walking distance(6MWD),NT-proBNP,tumor necrosis factor-α(TNF-α),hs-CRP,hs-cTnT,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVIDd),left ventricular end-systolic diameter(LVIDs),cardiac output(CO),E/A value,rehospitalization rate and side effects were compared between the two groups before and after treatment.Results The improvement of 6MWD,NT-proBNP,TNF-α,hs-CRP,hs-cTnT,LVEF,LVIDd,cardiac output(Co),E/A value,clinical effect and rehospitalization rate in the observation group were significantly superior to those in the control group(P<0.05).There was no significant difference in the incidence of LVIDs and adverse reactions between the two groups(P>0.05).Conclusion In HF-rEF patients,Empagliflozin is effective in the treatment of heart failure with reduced ejection fraction,and can significantly improve the clinical symptoms,cardiac function and quality of life,with less adverse reactions and higher safety.

关 键 词：恩格列净 心力衰竭 氨基末端脑钠肽前体 肿瘤坏死因子Α 超敏C反应蛋白 6 min步行试验 

分 类 号：R54[医药卫生—心血管疾病]